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ABSTRACT
Introduction Electronic prescribing (ePrescribing) is a key 
area of development and investment in the UK and across 
the developed world. ePrescribing is widely understood as 
a vehicle for tackling medication- related safety concerns, 
improving care quality and making more efficient use 
of health resources. Nevertheless, implementation of an 
electronic health record does not itself ensure benefits for 
prescribing are maximised. We examine the process of 
optimisation of ePrescribing systems using case studies to 
provide policy recommendations based on the experiences 
of digitally mature hospital sites.
Methods and analysis Qualitative interviews within six 
digitally mature sites will be carried out. The aim is to 
capture successful optimisation of electronic prescribing 
(ePrescribing) in particular health systems and hospitals. 
We have identified hospital sites in the UK and in three 
other developed countries. We used a combination of 
literature reviews and advice from experts at Optimising 
ePrescribing in Hospitals (eP Opt) Project round- table 
events. Sites were purposively selected based on 
geographical area, innovative work in ePrescribing/
electronic health (eHealth) and potential transferability of 
practices to the UK setting. Interviews will be recorded and 
transcribed and transcripts coded thematically using NVivo 
software. Relevant policy and governance documents will 
be analysed, where available. Planned site visits were 
suspended due to the COVID-19 pandemic.
Ethics and dissemination The Usher Research Ethics 
Group granted approval for this study. Results will be 
disseminated via peer- reviewed journals in medical 
informatics and expert round- table events, lay member 
meetings and the ePrescribing Toolkit (http://www. 
eprescribingtoolkit. com/)—an online resource supporting 
National Health Service (NHS) hospitals through the 
ePrescribing process.
BACKGROUND
International interest from private sector 
vendors and governments in electronic 
prescribing (ePrescribing) in hospitals over 
the last two decades can be understood as 
part of a wider initiative to develop eHealth 
capabilities in economically developed coun-
tries.1 The UK Department of Health and 
Social Care allocated £68 million for the 
period of 2018–2021 to further develop and 
improve electronic prescribing and medicines 
administration systems in NHS trusts. In the 
NHS Long Term Plan,2 trusts are encouraged 
to significantly enhance their digital capacity 
with regard to ePrescribing by 2029. In many 
UK hospitals, significant digital infrastruc-
ture exists even though it is not used to its 
full capacity. While in others, large- scale 
implementation of new electronic systems 
will be required.3 Much of the investment in 
ePrescribing is predicated on the hope that 
it will ultimately improve safety, quality and 
efficiency across medicines administration 
pathways.4–6 Making prescribing informa-
tion legible and sharable for those involved 
addresses the conditions that have led to the 
problem of adverse drug events .7 8 An advan-
tageous by- product of increased digitisation is 
the accompanying increase in the availability, 
variety and quality of data, which can be used 
for monitoring and evaluation purposes.2 
Digitisation also makes data useable for a 
variety of potential purposes such as clinical 
research as well as sophisticated population 
health management.2
Strengths and limitations of this study
 ► A strength of this study is the way in which it con-
textualises the question of what works in electronic 
prescribing (ePrescribing) optimisation using a case 
study approach.
 ► By targeting the most advanced sites, the study 
could miss interesting developments in sites that 
may have nevertheless made significant and useful 
progress in improving their ePrescribing process.
 ► This study will involve both patient representatives 
and experts in clinical informatics throughout the 
project to guide research questions and add context 
to the research findings.
 ► It will not be possible to conduct direct observations 
of optimised medication prescribing processes in 
action, which will limit data triangulation.
 ► The study forms part of a wider multiphase research 
project that will collectively give a nuanced under-
standing of optimisation in ePrescribing.
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The Wachter Review was commissioned to look at the 
lessons learnt from the perceived failures of the National 
Programme for IT (NPfIT), which ran from 2002 for 9 
years with the aim of digitising secondary care.9 The 
Wachter Review emphasised that ‘Going live with a health 
IT system is the beginning, not the end’.10 After the ‘Go 
Live’ and the subsequent stabilisation of the electronic 
health record (EHR), optimisation is the process of 
making adjustments to improve the system in situ. System 
optimisation in the context of health information tech-
nology has been described as ‘the organisational efforts 
to maximise the benefits and minimise the risks of util-
ising digital infrastructure to plan and deliver care’.11 
Problems with the lack of integration of various types of 
ePrescribing systems have been highlighted as potential 
threats to safety.6 The integration of numerous infor-
mation sources into clinical decision support (CDS) for 
ePrescribing was designed to ensure things like harmful 
drug–drug interactions and contraindications for partic-
ular patients with regard to specific drugs could be avail-
able at the point of prescribing.6 This in itself potentially 
creates safety challenges if clinical staff are distracted 
and delayed by alerts.3 On the one hand, an integrated 
system offers synchronisation between hospital activities, 
but in some cases, the variety of information, which can 
now be fed into the CDS, can worsen the problem of alert 
fatigue.8 Therefore, updates and perceived improvements 
to ePrescribing systems may introduce as well as mitigate 
risks.3 Despite significant investment and progress, the 
quality and functionality of digital health infrastructure 
and the integration of ePrescribing functionalities within 
these systems remain variable.10 Questions regarding inte-
gration of different hospital systems and the ability of staff 
to interact with changing functionalities continue to raise 
safety concerns.6
Previous work has identified a typology of optimisa-
tion targets falling within three broad areas. These are 
misalignment, enhancement and developing user capa-
bilities.12 Misalignment is the mismatch of what an organ-
isation needs the ePrescribing system to do and what it is 
capable of doing—its functionality. This can be addressed 
not only by configuring the system, adopting hardware 
and supporting infrastructure but also by changing 
existing ways of working. Enhancement seeks to improve 
the system by extending its reach in terms of integration 
of new information sources or ensuring more of the 
system’s existing functionality is employed. In developing 
user capabilities with the ePrescribing system, healthcare 
organisations typically focus on areas such as staff moti-
vation, competence and training. Variability between 
different implementations has been attributed to the 
need for a process of convergence between technology 
and local organisational characteristics.12
A qualitative study within four early adopter sites in the 
USA following the implementation of an ePrescribing 
system (referred to as computerised provider order entry 
systems in the US context) aimed to identify important 
lessons that future implementers should consider.13 The 
findings indicated that successful implementation was 
accompanied by adequate user training, clear gover-
nance procedures and pre- emptive action with regard to 
user perceptions and the fear of change.13 Additionally, 
a questionnaire- based study identified important factors 
associated with successful implementation of ePrescribing 
systems in English hospitals, reporting similar results.14 
Specifically, respondents indicated increased guidance 
around system choice, implementation strategy and stan-
dards, in addition to the support of top- level management 
to ensure projects were adequately resourced.14
Potentially, the introduction of ePrescribing can do 
more than simply transferring practices involved in a 
paper- based prescribing system into an electronic form; 
it can also provide opportunities for innovative ways of 
working.8 Much of what makes an ePrescribing system 
yield the desired functionality at local level depends on 
having the necessary informatics and clinical and phar-
macy staff available and engaged in the complex work 
of configuration.8 However, extensive configuration of 
systems as a local level raises questions of the scalability 
of successful ePrescribing optimisation processes and 
practices. Optimisation, therefore, can be a process 
of balancing national policies, negotiations with EHR 
vendors and local and organisational factors.12 The 
current situation of different vendors and informatics 
teams configuring systems in one or more hospitals raises 
questions of interoperability and shared information 
governance across the NHS. One of the recommenda-
tions made by the Wachter Review was not to overcorrect 
for the perceived drawbacks of the centralised approach 
of the NPfIT.10 The goals of interoperability, shared stan-
dards and data reuse and sharing to support both person-
alised care and research remain central to the vision for 
the NHS.2 15
eP OPT Project
In general, we can assume that digital maturity is an 
important attribute of hospitals, which can be used as 
benchmarks for advanced ePrescribing practices and 
processes. This is because their longer history of digitisa-
tion potentially provides more time post implementation 
to make interventions to ePrescribing systems and assess 
their impact—provided the requisite resources and exper-
tise have been available. It is assumed here that dissem-
ination of successful optimisation strategies adopted by 
digitally mature sites—both locally and internationally—
is likely to be helpful to those currently seeking to make 
similar improvements to their systems. We acknowledge, 
however, that the difference between implementation 
and optimisation may not always be clear. Adequately 
resourced later adopters may be in a position to imple-
ment systems, such as closed- loop medication, which 
have been part of an optimisation process for those with 
a longer digital history. Indeed, in the UK Global Digital 
Exemplars (GDE) Programme, there have been proac-
tive strategies employed to ensure that later adopters of 
electronic health systems learn lessons that have taken a 
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number of years for their earlier adopting counterparts to 
learn.16 In this context, exemplars are digitally advanced 
NHS trusts who can share their learning with other trusts 
to improve their digital and informatics capabilities. More-
over, integrating an ePrescribing system into secondary 
care is a complex process likely involving different profes-
sionals and systems, as well as adjustments to fit local, 
specialisation- specific and policy requirements.
The Optimising ePrescribing in Hospitals (eP Opt) 
Project was conceived in response to the complexities 
involved in optimising ePrescribing systems, coupled with 
recent recommendations for further digitisation within 
NHS hospitals.2 17–19 The qualitative study described 
here is part of this larger project, the aim of which is to 
comprehensively investigate how best to optimise hospital 
ePrescribing systems through four distinct study phases.
This paper presents the study protocol for Phase 2 of 
the project and will detail how it contributes to a compre-
hensive investigation of approaches to optimise ePre-
scribing systems in English hospitals within the wider eP 
Opt Project.
METHODS AND STUDY DESIGN
A model of allowing more digitally mature hospitals to 
lead the way in the digitisation of healthcare has devel-
oped as a strategy in revealing useful insights to aid future 
health IT programmes.8 This model has been embodied 
by the GDE Programme.11 Our approach within eP Opt 
will involve examining the practices and processes of 
digitally mature hospitals. Their experiences will act as 
benchmarks for making improvements to ePrescribing 
systems to be adopted by sites across the NHS.
Study aims and objectives
The aim of the qualitative study will be achieved through 
the following objectives:
1. Identifying and gaining access to digitally mature sites 
that have extensively optimised the EHR/ePrescribing 
systems.
2. Gain in- depth accounts of experiences with optimisa-
tion strategies from key members of staff within these 
sites.
3. Contrast responses within and between study sites and 
between UK- based and international sites.
Study interaction between wider project phases
This study will be conducted and reported in accordance 
with the consolidated criteria for reporting qualitative 
research checklist.20 The study presented in this protocol 
is a standalone research project but will interact with the 
wider project contributing to a comprehensive under-
standing of the range of approaches taken to optimising 
ePrescribing systems in NHS hospitals. A brief description 
of how each project phase compliments this current study 
is given below and summarised in figure 1.
Phase 1: A scoping review of optimisation strategies for ePre-
scribing in hospitals. Published literature reporting on 
interventions to optimise ePrescribing systems in Organ-
isation for Economic Cooperation and Development 
(OECD) countries was collated using a scoping review 
methodology.21–23 Results were then mapped to assess 
the various different optimisation strategies used and 
identify effective interventions. This phase assisted in the 
identification of leading sites to explore further in this 
present study (Phase 2), as well as geographical areas with 
higher levels of activity in optimisation of ePrescribing. A 
detailed description of Phase 1 is provided elsewhere.24
Phase 3: Expert round- table discussions. From our initial 
roundt- able events, it has emerged that the difficulties 
around stating exactly what the optimisation of ePre-
scribing entails present challenges in defining what would 
constitute doing this successfully. The tension between 
allowing local innovation to flourish with highly configu-
rable systems and interoperability and sharing across the 
NHS as a whole was highlighted. Caution was urged on a 
number of topics including the idea that lessons from one 
context can easily be applied in another, wherein cultural, 
infrastructural and even regulatory parameters may be 
impactful. This applies also to the scalability of lessons in 
the NHS and potential financial constraints faced by some 
UK sites. It may not be feasible for NHS trusts to emulate 
some of the successful strategies found in other national 
contexts where different funding models are in opera-
tion. These insights have informed research questions for 
Figure 1 The four phases of the EP Opt Project and interactions between phases, demonstrating how Phase 2 is situated 
within the wider project. The project is intended to provide recommendations relevant to the UK National Health Service (NHS).









pen: first published as 10.1136/bm




4 Heeney C, et al. BMJ Open 2021;11:e044622. doi:10.1136/bmjopen-2020-044622
Open access 
this present study (Phase 2) and the interview topic guide 
used during data collection and will shape how the results 
are turned into recommendations.
Phase 4: Literature review of international ePrescribing policy. 
A literature review of academic literature and grey litera-
ture around international policies relating to optimising 
ePrescribing capabilities across OECD countries. This 
phase will demonstrate local and national attempts to 
implement and adopt policies to optimise ePrescribing 
systems. Again, the end- point is to consider lessons to be 
applied in the UK policy context.
Selection of case study sites and participant recruitment
In order to identify key, digitally mature sites to be 
approached as case studies, we will employ the following 
strategies. First, key publications identified in Phase 1 
of the eP Opt Project will be used to identify healthcare 
institutions that have a major focus on developing/evalu-
ating optimised ePrescribing systems and practices inter-
nationally. Second, Phase 3, which runs throughout the 
life course of the eP Opt Project, enables us to have access 
to experts in UK and international research and policy in 
ePrescribing who have pointed us towards relevant digi-
tally mature sites. Additionally, during expert round- table 
discussions, attending clinicians provide information on 
innovative optimisation work being carried out in the UK 
and internationally. In Phase 2 of the project, we aim to 
build on previous work on ePrescribing by looking specifi-
cally at optimisation. Sites within the UK and other OECD 
countries have been selected on the basis of evidence of 
digital maturity, innovation and success in ePrescribing. 
These sites can be expected to have been using electronic 
systems for medicine management for 5–15 years, in 
which time they will have had ample opportunity to make 
improvements to the system.
Once agreements in principle had been gained from 
the initial site contacts, we will then employ a purpo-
sive sampling strategy to recruit staff from each site who 
have been involved in aspects of optimising ePrescribing 
systems and system users. Semistructured interviews will 
be carried out with a range of professionals involved in the 
optimisation of ePrescribing including doctors, nurses, 
pharmacists, IT specialists/data analysts, managers and 
representatives of EHR system supplier. We aim to carry 
out approximately 10 qualitative key informant interviews 
within each benchmark site (approximately 60 inter-
views in total). Initial contacts at each site were asked to 
provide email addresses for relevant staff members who 
are involved in system optimisation, before emails were 
then sent explaining the project and providing informa-
tion sheets. If intent to participate was then indicated, 
participant consent forms were provided, and interviews 
were arranged.
Data collection
Qualitative semistructured interviews will be used to 
explore participants’ experiences with optimising and 
using ePrescribing systems within their respective sites. 
Interviews will be guided by an interview topic guide 
and will specifically seek to elicit interviewees’ experi-
ences of improving or adjusting an existing EHR system 
for ePrescribing purposes, staff deployment/training, 
governance, specific examples of optimisation and policy 
drivers. We will also explore the boundary between the 
implementation and optimisation process, the problems 
that optimisation strategies have attempted to solve, expe-
rience with suppliers and unexpected consequences of 
making improvements to the system. Originally, face- to- 
face interviews were planned; however, the impact of the 
COVID-19 pandemic has meant that all data collection 
will now take place virtually using tele/videoconferencin 
software. Therefore, planned direct observation of ePre-
scribing practices at study sites will also not be possible.25 
Interviews will be undertaken by two researchers with 
extensive training and experience in conducting qual-
itative research. All participants will be provided with 
information sheets and asked to sign informed consent 
forms prior to the interview. It will be made clear that 
participation in all or part of the interview is voluntary. 
All interviews will be audio recorded. All audio files will 
be transcribed verbatim by a professional transcription 
company.
Analysis
Transcripts of interviews will be analysed using induc-
tive thematic analysis,26 whereby coding will be applied 
to data to identify emerging themes and generate new 
theory. After familiarising themselves with the dataset, 
two researchers (CH and SM) will independently code 
two transcripts before discussing any discrepancies in the 
assignment of codes, to develop and refine the coding 
framework and establish intercoder consistency.27 28 Both 
researchers will then use the finalised coding framework 
to code the remaining transcripts, before reconvening 
to group the emerging codes into broader themes and 
subthemes. The researchers will employ prospective 
reflexivity during data collection and analysis to reduce 
the impact of bias on both the data collected and the 
interpretation of the findings.29 Data analysis will be 
conducted using NVivo V.12 Pro qualitative data analysis 
software.
Patient and public involvement
A major component of the eP Opt Project is the involve-
ment of patient and public representatives across the 
four project phases. Specifically, two patient and public 
involvement (PPI) representatives are involved as team 
members, who attend research meetings and public events 
to provide feedback and suggestions on the work within 
each phase from a patient’s perspective. They have also 
been extensively involved with assisting with the design of 
an upcoming PPI round- table event for Phase 3 of the eP 
Opt Project, where current progress of the present study 
will be shared with a group of invited patients and their 
feedback gathered to be used as the study progresses. 
These round- table events and PPI consultations have 
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helped in the formulation of research questions and will 
feed into analysis of the data by highlighting current gaps 
in practice from a patient perspective.
Study timeline
Benchmark site recruitment started in autumn 2019. All 
six identified sites were initially contacted by the end of 
2019, and access has been granted to begin recruitment 
and conduct interviews in four of the six sites. At present, 
we plan to continue recruitment for sites and individuals 
iteratively until at least 10 participants have been recruited 
from each site. Data collection commenced in March 
2020 and is anticipated to be completed by early 2021. 
We have experienced delays in recruitment as access to 
hospital staff and availability were affected by COVID-19. 
We aim to have data analysis completed by February 2021, 
with dissemination of findings anticipated in early 2021.
DISCUSSION
Optimisation of ePrescribing systems can be seen as an 
ongoing process of identifying gaps in functionality of an 
already implemented system and negotiating changes, 
which would address these gaps, and is a complex, multi-
faceted process. The qualitative study described in this 
protocol sits within a multiphase research project that 
aims to comprehensively investigate approaches to take 
when optimising ePrescribing systems and to highlight 
important lessons to be learnt as ePrescribing continues 
to be implemented at scale within the NHS.2 This study 
will gather the insight of healthcare professionals at 
leading benchmark sites in both the UK and internation-
ally. All phases of the wider eP Opt Project investigate the 
journey from implementation of an EHR with associated 
ePrescribing functionality to these systems performing as 
an optimal resource for professionals and patients. This 
addresses the important question of unintended conse-
quences of ePrescribing systems and attempts to ensure 
that the safety of prescribing processes is not adversely 
affected as improvements are made.
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